A Guardian investigation reveals asbestos in children's toys sold in the UK, raising concerns about product safety and regulatory enforcement.
A recent Guardian investigation found asbestos fibres in five of six children's toys tested that were still being sold in Britain, despite UK laws banning the sale of products containing any amount of asbestos. Several of the toys were similar to products that had already been recalled in the Netherlands.
The findings raise fresh concerns about the UK's product safety regime, which relies heavily on manufacturers and retailers identifying and reporting risks themselves. The Investigation also highlighted inconsistencies between jurisdictions, with products removed from sale elsewhere in Europe remaining available to UK consumers.
The affected items included sand-art kits and novelty toys sold through online retailers and marketplaces. Following the investigation, some products were withdrawn and further investigations launched by sellers.
In response, the Office for Product Safety and Standards, UK Health Security Agency and Health and Safety Executive issued joint guidance on asbestos-contaminated consumer products. While asbestos-containing products must be removed from sale and recalled, the response stressed that the presence of asbestos does not automatically create an immediate health risk. The level of risk depends on whether fibres are released and inhaled, and the extent of exposure. For the products identified so far, the expected health risk from normal use and occasional short-term exposure is considered low.
Businesses do however remain legally responsible for product safety, and Regulators say they will continue monitoring the issue and taking enforcement action where necessary.
The question is though, if asbestos is finding its way into everyday consumer products despite a decades-old ban, will these seemingly low-risk exposures become tomorrow's litigation—and another chapter in the long story of asbestos-related claims?
Whether you’re assessing product liability exposure, responding to regulatory scrutiny or preparing for future disease claims, our Disease team provides practical, strategic advice to help organisations manage risk with confidence. To discuss the issues raised in this article, please contact Peter Ward or another member of the occupational disease team.
